Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

NAGE EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Niagen Bioscience IncNASDAQ: NAGE

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q1 FY2026 EBITDA of $7.03M rose 25.5% year over year, behind the +33.4% change in trailing-twelve-month EBITDA. Sequentially, it rose 32.9% from the prior quarter.

Context

  • EBITDA amounted to 15.2% of revenue in FY2025, up 4.8 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $7.37M (-62.5%) for the fiscal year ending Dec 2026, a slowdown from the +90.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.03M+32.9% QoQ
Last fiscal yearDec 2025
$19.64M+90.0% YoY
LTMMar 2026
$21.4M+33.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.5%-68.1%-93.6 pp
1 year+90.0%-62.5%-152.5 pp
3-year CAGR—-8.5%—
5-year CAGR+18.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
19.64M USD
Year-over-year change
+90.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How NAGE compares with its peers on the latest reported figures

  • NAGE's LTM Mar 2026 EBITDA of $21.4M is the 3rd highest of the 10 companies compared; the peer median is -$74.72M.
  • Its year-over-year change of +33.4% is the 4th highest of 9, against a peer median of -23.0%.
  • EBITDA amounts to 16.4% of revenue for NAGE, versus a peer median of 114.9%.
NAGE Competitors Peer median
EBITDA for NAGE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$140.47M +332.9%—114.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$131.28M +170.9%—43.8%
NAGENiagen Bioscience IncLTM Mar 2026$21.4M +33.4%—16.4%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-$5.76M -220.1%+92.3%2.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$42.27M -2.3%——
PRTAProthena Corporation plcLTM Mar 2026-$74.72M +35.0%—129.0%
KROSKeros Therapeutics, Inc.LTM Mar 2026-$88.74M -376.4%—267.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-$117.15M ——101.1%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$184.67M -43.8%——
RGNXREGENXBIO Inc.LTM Mar 2026-$229.35M -87.3%—261.2%
Peer median (excluding NAGE) -$74.72M-23.0%+92.3%114.9%

Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue67.45M72.05M83.57M99.6M129.42M
Cost of Revenue25.96M29.25M32.79M38.01M46.23M
Gross Profit41.49M42.8M50.78M61.59M83.19M
Gross Margin61.5%59.4%60.8%61.8%64.3%
Research & Development3.83M4.83M4.96M6.02M6.33M
Selling, General & Admin64.73M56.6M51.42M47.84M62.56M
Operating Expenses68.56M61.43M56.38M53.86M68.89M
Depreciation & Amortization1.63M1.88M1.71M1.48M1.45M
EBITDA(25.45M)(14.66M)(3.23M)10.34M19.64M
EBITDA Margin-37.7%-20.3%-3.9%10.4%15.2%
Operating Income(27.07M)(18.63M)(5.6M)7.73M14.3M
Operating Margin-40.1%-25.9%-6.7%7.8%11.0%
Interest Income03K661K1.13M2.13M
Interest Expense55K0000
Other Income / Expenses(55K)2.09M661K1.13M3.9M
Income Before Tax(27.13M)(16.54M)(4.94M)8.86M18.19M
Pre-Tax Margin-40.2%-23.0%-5.9%8.9%14.1%
Income Tax Expense000305K810K
Net Income(27.13M)(16.54M)(4.94M)8.55M17.38M
Net Margin-40.2%-23.0%-5.9%8.6%13.4%
EPS (Basic)(0.40)(0.24)(0.07)0.100.22
EPS (Diluted)(0.40)(0.24)(0.07)0.110.20
Weighted Avg Shares67.19M68.92M70.54M85.42M79.18M
Weighted Avg Shares (Diluted)67.19M69.73M74.99M79.72M85.44M

Niagen Bioscience Inc

NASDAQ:NAGE

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.